- 主题
- 70
- 您的身份
- 病友
- 就诊医院
- 杜克医院
- 病理报告
- 脾边缘带B细胞淋巴瘤
- 目前状态
- 康复5-10年
参加活动:0 次 组织活动:0 次
您的身份病友
病理报告脾边缘带B细胞淋巴瘤
就诊医院杜克医院
目前状态康复5-10年
最后登录2022-9-27

|
发表于 2019-9-7 23:11:39
|
显示全部楼层
来自: 美国
本帖最后由 雨人山 于 2019-9-7 23:19 编辑
你理解错了。我说的不是遗传,是基因变异。看看这篇文章 (Clin Cancer Res; 21(18); 4174–83. ©2015 AACR.)说的是脾边缘带的影响预后的基因变异的问题,这样的文章很多。科学不是民科啊!
This multinational study identifies genomic and immunogenetic factors with prognostic significance in splenic marginal zone lymphoma (SMZL), a rare B-cell non–Hodgkin lymphoma. Genomic mutations in TP53, KLF2, NOTCH2, and TNFAIP3 were found collectively in more than 40% of cases and 13% used IGHV genes with no somatic hypermutation (SHM). TNFAIP3 mutations were associated with an increased risk of high-grade transformation. IGHV genes lacking SHM, KLF2, and NOTCH2 mutations were associated with shorter time-to-first treatment, whereas TP53 and MYD88 mutations were predictors of short and long overall survival, respectively. In contrast to cytogenetic and FISH data, NOTCH2 and TP53 mutations remained independent factors of outcome in multivariate analyses which included the established prognostic markers: anemia and thrombocytopenia. Genomic and immunogenetic data have the potential to aid diagnosis and influence the timing and choice of treatment in SMZL.
|
|